Gene therapy may be having challenges getting there - but it's clearly the long term solution. For that reason NNZ-2591 likely has a limited window in this area - successful gene therapy will always be coming. HIE (not to mention the next logical future steps after HIE - stroke & TBI...) doesn't have this competitive risk.
You are correct,
After I watched this interesting video, it appears Neuren has the lead, but some years behind, is a very promising gene therapy. The person who speaks has a disclosure at the start where he outlines his involvement with companies involved in PMS, which shows his reach. Neuren gets talked about in a very positive light just after the 8-minute mark. Not much else comes close currently. PYC gets a mention, but the gene therapy he talks about at the end seems like a real prospect.
I have had a look around but haven't seen this video posted, apologies if it has been.
NEU Price at posting:
$13.88 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)